Recommendation ID
Trials of erythropoiesis-stimulating agents (ESAs) in children:- Trials of ESAs in children with anaemia of chronic kidney disease (CKD) (including darbepoetin, which is currently not licensed for use in children younger than 12 years) including safety, dosing and efficacy outcomes.
Any explanatory notes
(if applicable)
Why this is important:- There is very little evidence relating to anaemia of chronic kidney disease (CKD) in children. Erythropoiesis-stimulating agents (ESAs) are a key therapy and therefore more data are needed in order to define suitable treatment regimens.

Source guidance details

Comes from guidance
Anaemia management in people with chronic kidney disease
Date issued
February 2011

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No